Health Care & Life Sciences » Biotechnology | CrystalGenomics Inc.

CrystalGenomics Inc. | Income Statement

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Sales/Revenue
4,796
4,536
6,136
14,525
12,175
Cost of Goods Sold (COGS) incl. D&A
3,350
4,286
1,536
5,486
3,997
Gross Income
1,446
249
4,600
9,039
8,178
SG&A Expense
7,285
6,996
8,530
13,065
14,487
EBIT
6,039
7,229
-
4,090
6,416
Unusual Expense
3,538
1,219
672
599
161
Non Operating Income/Expense
20
23
1,394
1,034
417
Interest Expense
3,877
4,858
3,568
1,802
1,178
Pretax Income
12,751
12,961
6,417
4,021
10,247
Income Tax
1,960
659
632
608
158
Equity in Affiliates
615
371
793
1,082
-
Consolidated Net Income
11,406
11,931
4,992
3,547
8,575
Net Income
11,406
11,931
4,992
1,960
8,575
Net Income After Extraordinaries
11,406
11,931
5,134
1,741
8,575
Net Income Available to Common
11,406
11,931
4,850
2,179
8,575
EPS (Basic)
474.62
435.32
157.20
65.75
238.82
Basic Shares Outstanding
24
27
31
33
36
EPS (Diluted)
474.66
435.18
156.86
65.44
238.93
Diluted Shares Outstanding
24
27
31
33
36
EBITDA
4,637
5,867
2,759
2,369
4,948
Other Operating Expense
200
482
62
63
107
Non-Operating Interest Income
683
321
420
237
421
Minority Interest Expense
-
-
-
1,587
-
Equity in Affiliates (Pretax)
-
-
-
-
2,497
Other After Tax Income (Expense)
-
-
-
-
1,829

About CrystalGenomics

View Profile
Address
5/F, Tower A, Korea Bio Park
Seongnam GY 13488
Korea, Republic Of
Employees -
Website http://www.crystalgenomics.com
Updated 09/14/2018
CrystalGenomics, Inc. engages in the discovery and development of novel therapeutics. The company operates through following business divisions: Research and Development, New Drug Development division, New Drug Sales, Products Sales, and Real Estate Leasing. The Research and Development division provides analysis of clinical trials services.